

ARHAI MEMBER	PERSONAL INTERESTS		NON-PERSONAL INTERESTS	
	Name of organisation	Nature of interest	Name of organisation	Nature of interest
Professor Mike Sharland	CEPHALON, GSK CLAHRC NICE	Advisory Board Fees Research funding independent scientific advisor (paid)	Pfizer NIHR, EU and medical charities	Institutional research funding to conduct observational studies of antibiotic use in acute otitis media Non-pharma academic grants
Ms Isabel Boyer	None	None	None	None
Ms Jane Binyon	None	None	None	None
Professor Peter Hawkey	AstraZeneca, Biomeriux, Eumedica, Merck, Novartis, Pfizer Modus Medica	Consultancies Lectures in past 3 years Director and shareholder	Pfizer Novartis	Research funding in past 3 years
Professor Alan Johnson	Astellas	Lecture honorarium	None	None
Mr Martin Kiernan	Gabriel Scientific Gama Healthcare Vernacare	Advisory Board memberships, Consultancy, Lectures	None	None
Dr Cliodna McNulty	None	None	None	None
Professor Michael Moore	Partner in a GP practice delivering healthcare to the local population under GMS regulations.	Part owner of a pharmacy hosted in the same building providing general pharmaceutical services (prescription medication) to the public	Danone RCGP	Travel expenses for conference in past 2 years. National Clinical Champion for antimicrobial stewardship
Professor Mark Wilcox	Actelion, Astellas, Astra-Zeneca, Bayer, Cerexa, Cubist, Durata, The Europea Tissue Symposium, The Medicines Co, MedImmune, Merck, Motif Biosciences, Nabriva, Optimer, Paratek, Pfizer, Roche, Sanofi-Pasteur ,Seres, Summit, Synthetics Biologics	Consultancies and/or lecture honoraria in the past 2 years	Abbott, Actelion, Astellas, bioMerieux, Cubist, Da Volterra, The European Tissue Symposium, Merck and Summit	Have funded research in the past 2 years.
Professor APR Wilson	Roche and Quintiles DSMB IMC Partnership Corning	Member UCLH private hospital infection control Research funding	Biomimetics, Steris	Contract work
Professor David Livermore	Achaogen, Adenium, Altermune, Alere, Allecra, AstraZeneca, Astellas, Auspherix, Basilea, Bayer,	Advisory Board/ Consultancy	Achaogen, Allecra, AstraZeneca, Basilea, Cubist, GSK, Longitude, Meiji, Melinta,	Contract research in past 3 years run via employer (Public Health England)

	<p>BioVersys, Canaan Capital, Cubist, Curetis, Cycle, Discuva, Forest, GSK, Longitude, McKinsey, Meiji, Pfizer, Roche, Shionogi, Tetrphase, VenatoRx, Wockhardt</p> <p>Dechra, GSK, Merck, Perkin Elmer, Pfizer</p> <p>AOP Orphan, AstraZeneca, Astellas, Bruker, Curetis, Leo, Merck, Pfizer</p>	<p>Shareholder</p> <p>Paid Lectures</p>	<p>Tetrphase, VenatoRx, Workhardt,</p>	
Dr Kieran Hand	<p>Astra Zeneca, Cubist, Forest, Pfizer</p>	<p>Advisory board fees</p>	<p>Astellas</p> <p>Astellas, Forest, Gilead</p>	<p>Sponsors an annual award for good prescribing at place of work (University Hospital Southampton NHS Foundation Trust)</p> <p>Conference attendance sponsorship</p>
Professor Alastair Hay	<p>University of Bristol</p> <p>NICE</p> <p>NIHR HTA Trials' Board</p>	<p>Academic post and lead for primary care infection group</p> <p>Chair of NICE Antimicrobial Stewardship Guideline Development Group (until approx. July 2015)</p> <p>Member</p>	<p>None</p>	<p>None</p>